Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Delcath Systems ( (DCTH) ) has shared an update.
On January 9, 2026, Delcath Systems released preliminary, unaudited financial and operational results for the fourth quarter and full year 2025, reporting expected total revenue of about $20.7 million for the quarter and $85.2 million for the year, driven largely by HEPZATO KIT sales of approximately $19.0 million and $78.8 million, respectively, with CHEMOSAT contributing $1.7 million in the quarter and $6.4 million for the year. As of December 31, 2025, the company reported 25 active centers using HEPZATO KIT, approximately 34.7 million shares outstanding, positive operating cash for the quarter, $91.0 million in cash and short-term investments with no debt, and the repurchase of 628,572 common shares for $6.0 million under its $25.0 million buyback program, while highlighting roughly 140% growth in HEPZATO procedure volume in 2025 versus 2024 and new clinical and publication data supporting its percutaneous hepatic perfusion platform; management emphasized that the figures are preliminary and subject to change pending completion of the year-end audit.
The most recent analyst rating on (DCTH) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.
Spark’s Take on DCTH Stock
According to Spark, TipRanks’ AI Analyst, DCTH is a Neutral.
Delcath Systems shows strong financial performance with robust cash flow and minimal leverage. Positive clinical trial results and a share buyback plan enhance future prospects. However, the stock’s high P/E ratio suggests overvaluation, and mixed technical indicators point to potential volatility. The earnings call provided a balanced view of growth opportunities and challenges.
To see Spark’s full report on DCTH stock, click here.
More about Delcath Systems
Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers. Its proprietary HEPZATO KIT, a drug-device combination approved in the United States for liver-directed treatment of metastatic uveal melanoma, and the CHEMOSAT Hepatic Delivery System in Europe are designed to deliver high-dose melphalan chemotherapy directly to the liver via percutaneous hepatic perfusion while limiting systemic exposure and side effects, and are used at major medical centers for a range of liver cancers.
Average Trading Volume: 840,969
Technical Sentiment Signal: Sell
Current Market Cap: $360.6M
See more data about DCTH stock on TipRanks’ Stock Analysis page.